HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease.

Abstract
Despite the apparent neurotoxicity of amyloid-β (Aβ), recent clinical trials of Aβ immunotherapy have not shown any clinical benefit in Alzheimer's disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in promoting amyloidogenic evolvability in reproduction, which may result in the adiponectin paradox through antagonistic pleiotropy mechanism in aging, leading to AD. Accordingly, preventing the adiponectin paradox by suppressing adiponectin signaling might prove therapeutic in AD.
AuthorsMasaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, Ryoko Wada, Shuei Sugama, Takato Takenouchi, Eliezer Masliah, Makoto Hashimoto
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 76 Issue 4 Pg. 1249-1253 ( 2020) ISSN: 1875-8908 [Electronic] Netherlands
PMID32623396 (Publication Type: Journal Article)
Chemical References
  • ADIPOQ protein, human
  • Adiponectin
  • Amyloid beta-Peptides
Topics
  • Adiponectin (metabolism)
  • Aging (physiology)
  • Alzheimer Disease (drug therapy)
  • Amyloid beta-Peptides (metabolism)
  • Brain (metabolism)
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: